By Sabela Ojea
INmune Bio said its XPro1595 inhibitor has demonstrated remyelination, a natural process that restores myelin, in an animal model of demyelinating disease.
The clinical-stage company said the multi-year study, published in a seminal paper in the journal Cell Reports, has implications for many central nervous system diseases such as Alzheimer's.
Myelin is necessary for fast and efficient communication between neurons, the company said.
INmune expects to report top-line cognitive results of an ongoing blinded randomized Phase II in early Alzheimer disease patients in the first half of 2025.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
October 24, 2024 15:25 ET (19:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。